Piramal Pharma announces $90m investment to expand US sites
The Riverview, Michigan site is expected to be operational by the end of 2025.
Syngene Thematic ADC WP
FDA approves AstraZeneca and Daiichi Sankyo’s Datroway for NSCLC
Orion and Glykos extend ADC collaboration
NextCure and Simcere partner to develop SIM0505 for solid tumours
NICE approves GSK’s belantamab mafodotin for blood cancer
EC approves Takeda ADC plus chemo for stage IIb Hodgkin’s lymphoma
ASCO25: AbbVie flexes ADC Phase I data as NSCLC market opportunity beckons
ASCO25: Genmab’s Rina-S en route to ‘blockbuster potential’ amid further positive data
